OBJECTIVE: To examine the incidence and risk factors for anal cancer in a multicenter cohort of human immunodeficiency virus (HIV) positive and HIV-negative men who have sex with men followed between 1984 and 2006 (Multicenter AIDS Cohort Study). METHODS: Prospective analysis using Poisson regression and Cox proportional hazard models and a nested case-control study using conditional logistic regression. RESULTS: There were 28 cases of anal cancer among the 6,972 men who were evaluated. The incidence rate was significantly higher in HIV-positive men than in HIV-negative men (incidence rate = 69 vs 14 per 100,000 person-years). Among HIV-positive men, anal cancer incidence was higher in the highly active antiretroviral therapy (HAART) era than the pre-HAART era (incidence rate = 137 vs 30 per 100,000 person-years). In multivariate analysis restricted to the HAART era, anal cancer risk increased significantly with HIV infection (relative hazard = 4.7, 95% confidence interval = 1.3 to 17) and increasing number of unprotected receptive anal sex partners at the first 3 study visits (P trend = 0.03). Among HIV-positive men, current HAART use did not decrease anal cancer risk. CONCLUSIONS: HIV-positive men had increased risk of anal cancer. Improved survival of HIV-positive individuals after HAART initiation may allow for sufficient time for human papillomavirus-associated anal dysplasias to develop into malignancies, thus explaining the increased incidence of anal cancer in the HAART era.
OBJECTIVE: To examine the incidence and risk factors for anal cancer in a multicenter cohort of human immunodeficiency virus (HIV) positive and HIV-negative men who have sex with men followed between 1984 and 2006 (Multicenter AIDS Cohort Study). METHODS: Prospective analysis using Poisson regression and Cox proportional hazard models and a nested case-control study using conditional logistic regression. RESULTS: There were 28 cases of anal cancer among the 6,972 men who were evaluated. The incidence rate was significantly higher in HIV-positive men than in HIV-negative men (incidence rate = 69 vs 14 per 100,000 person-years). Among HIV-positive men, anal cancer incidence was higher in the highly active antiretroviral therapy (HAART) era than the pre-HAART era (incidence rate = 137 vs 30 per 100,000 person-years). In multivariate analysis restricted to the HAART era, anal cancer risk increased significantly with HIV infection (relative hazard = 4.7, 95% confidence interval = 1.3 to 17) and increasing number of unprotected receptive anal sex partners at the first 3 study visits (P trend = 0.03). Among HIV-positive men, current HAART use did not decrease anal cancer risk. CONCLUSIONS:HIV-positive men had increased risk of anal cancer. Improved survival of HIV-positive individuals after HAART initiation may allow for sufficient time for human papillomavirus-associated anal dysplasias to develop into malignancies, thus explaining the increased incidence of anal cancer in the HAART era.
Authors: Andrew E Grulich; Yueming Li; Ann McDonald; Patricia K L Correll; Matthew G Law; John M Kaldor Journal: AIDS Date: 2002-05-24 Impact factor: 4.177
Authors: J M Palefsky; E A Holly; M L Ralston; M Da Costa; H Bonner; N Jay; J M Berry; T M Darragh Journal: J Acquir Immune Defic Syndr Date: 2001-12-15 Impact factor: 3.731
Authors: Christophe Piketty; Teresa M Darragh; Isabelle Heard; Maria Da Costa; Patrick Bruneval; Michel D Kazatchkine; Joel M Palefsky Journal: Sex Transm Dis Date: 2004-02 Impact factor: 2.830
Authors: T Bjørge; A Engeland; T Luostarinen; J Mork; R E Gislefoss; E Jellum; P Koskela; M Lehtinen; E Pukkala; S Ø Thoresen; J Dillner Journal: Br J Cancer Date: 2002-07-01 Impact factor: 7.640
Authors: Seyram A Butame; Sylvia Lawler; Joseph T Hicks; J Michael Wilkerson; Lu-Yu Hwang; Sarah Baraniuk; Michael W Ross; Elizabeth Yu Chiao; Alan G Nyitray Journal: Cancer Causes Control Date: 2017-08-04 Impact factor: 2.506
Authors: Timothy J Wilkin; Huichao Chen; Michelle S Cespedes; Jorge T Leon-Cruz; Catherine Godfrey; Elizabeth Y Chiao; Barbara Bastow; Jennifer Webster-Cyriaque; Qinghua Feng; Joan Dragavon; Robert W Coombs; Rachel M Presti; Alfred Saah; Ross D Cranston Journal: Clin Infect Dis Date: 2018-10-15 Impact factor: 9.079
Authors: Emily A Burger; Michael A Dyer; Stephen Sy; Joel M Palefsky; Alexandra de Pokomandy; François Coutlee; Michael J Silverberg; Jane J Kim Journal: J Acquir Immune Defic Syndr Date: 2018-09-01 Impact factor: 3.731
Authors: Elizabeth Y Chiao; Christine M Hartman; Hashem B El-Serag; Thomas P Giordano Journal: J Acquir Immune Defic Syndr Date: 2013-08-15 Impact factor: 3.731
Authors: Timothy Wilkin; Jeannette Y Lee; Shelly Y Lensing; Elizabeth A Stier; Stephen E Goldstone; Michael J Berry; Naomi Jay; David M Aboulafia; Mark H Einstein; Alfred Saah; Ronald T Mitsuyasu; Joel M Palefsky Journal: HIV Clin Trials Date: 2013 Mar-Apr